Pulmonary complications and survival after autologous stem cell transplantation: predictive role of pulmonary function and pneumotoxic medications

[摘要] ExtractAutologous stem cell transplantation (ASCT) is the standard of care for multiple myeloma patients eligible for high-dose therapy; lymphoma patients undergoing second-line treatments and for acute myelogenous leukaemia (AML) [1]. Immune system impairment and chemotherapies significantly increase the risk of infections; particularly pneumonia [2]. Overall; pulmonary complications; both infectious and non-infectious; occur in 40xe2x80x9360% of patients after stem cell transplantation [3]; and are usually classixefxacx81ed as early or late onset; depending on whether they occur within 100xe2x80x85days of the transplant [4]. The underlying disease and baseline pulmonary function; along with conditioning regimens consisting of carmustine; etoposide; aracytin and melphalan for lymphoma; melphalan alone for multiple myeloma or busulpan and cyclophosphamide for acute myeloid leukaemia; all concur to cause pulmonary complications [3; 4].

[学科分类] 呼吸医学